EGF vs Leuphasyl

Binds EGFR (EGF receptor / ErbB1), activating RAS/MAPK and PI3K/Akt signaling cascades. Promotes keratinocyte and fibroblast proliferation, accelerates wound re-epithelialization, and stimulates collagen and hyaluronic acid production.

Epidermal growth factor (EGF) is an endogenous 53-amino-acid polypeptide that binds the EGF receptor (EGFR) to stimulate cell proliferation, migration, and differentiation in epithelial and mesenchymal cells; it plays a fundamental role in wound healing, skin regeneration, and tissue repair by promoting keratinocyte and fibroblast activation through tyrosine kinase-mediated downstream signaling. EGF activates EGFR tyrosine kinase to initiate PI3K/Akt and MAPK/ERK proliferative signaling cascades; in wound contexts, topically applied recombinant EGF accelerates epithelialization and granulation tissue formation, and injectable EGF has been evaluated for wound bed preparation in diabetic and chronic wounds. Clinical trials of recombinant human EGF for wound healing — including a PubMed-indexed human clinical trial in diabetic foot ulcers — have demonstrated improvements in wound closure and tissue regeneration; recombinant EGF preparations are approved in some countries (Cuba, South Korea) for diabetic wound healing under prescription conditions. Topically applied EGF has no FDA approval in the United States for wound healing or cosmetic applications; recombinant EGF-based wound therapeutics are available internationally under national regulatory approvals outside the US, and EGF is widely incorporated into cosmetic formulations at concentrations where receptor activation and clinical benefit have not been independently validated.

Tetrapeptide that mimics enkephalin to modulate facial muscle contraction; competes with enkephalin for opioid receptor sites in neuromuscular junctions; reduces repetitive muscle micro-contractions

Leuphasyl is a synthetic pentapeptide (Tyr-D-Ala-Gly-Phe-Leu-OH) designed as an enkephalin receptor mimic for topical cosmetic applications, formulated as a claimed anti-wrinkle active ingredient based on the theoretical premise that modulation of enkephalin receptor activity at facial neuromuscular junctions could attenuate dynamic muscle contraction and reduce the appearance of expression lines. The proposed mechanism involves enkephalin receptor interaction to attenuate acetylcholine release or signal transmission at the dermal-epidermal neuromuscular interface, conceptually analogous to botulinum toxin in mechanism but operating at significantly lower potency through a distinct receptor pathway; this theoretical framework draws on the established pharmacology of endogenous enkephalins at opioid and related receptors. No clinical trials, controlled in vivo studies, human safety data, or animal efficacy studies for leuphasyl as a distinct compound are indexed in PubMed; the compound appears exclusively in cosmetic ingredient databases and product formulation literature, with no peer-reviewed evidence base in any indexed scientific journal. Leuphasyl has no FDA approval, no drug regulatory status, and no published clinical evidence in any jurisdiction; it is a cosmetic peptide ingredient marketed on a theoretical mechanism, and any claims of efficacy in reducing wrinkles or expression lines are unsupported by independently published clinical or preclinical data.